The SGLT2 inhibitor agents empagliflozin and dapagliflozin both have been shown to reduce hospitalization rate for heart failure and improve renal outcome in subjects with T2DM, who had or were at a high risk for ASCVD [5,6]. The gene discussed is SLC5A2; the disease is atherosclerosis.